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Abstract
Background: Cases of drug induced liver injury still perplex gastroenterologists due to its wide range of presentations that mimic acute and 
chronic liver conditions. Moreover, matters get complicated when clinicians face the possibility of drug-induced injury in the presence of 
pre-existing chronic liver disease. Case: A 69 year-old male who was recently discovered to have a hepatitis C viral infection presented with 
acute manifestations (mixed cholangio-hepatocellular injury) not fully explained by the underlying chronic disease, we suspected an idiosyn-
cratic reaction from an esterified anabolic androgen. His manifestations have appeared acutely after the drug intake and include acute onset 
of jaundice, abdominal pain, pruritus and choluria. He was improving on drug discontinuity and conservative measures during his brief hos-
pital stay. Conclusion: The underlying chronic disease constitutes a dilemma in diagnosis of superimposed drug-induced liver injury, as the 
proof of causality is a daunting task. In such cases, it is tempting to link such new emerging manifestations to be a flare-up of the underlying 
chronic disease rather than to the drug. However, certain clues helped to point this clinical presentation towards a drug-induced liver injury.
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Introduction
Cases of drug induced liver injury (DILI) still perplex gastroente-
rologists due to its wide range of presentations that mimic acu-
te and chronic liver conditions. The liver is the most common 
organ prone to toxicity. However, the absence of internationally 
accepted diagnostic criteria for DILI along with underrepor-
ting and underrecognition make the overall incidence variable 
which ranges from 1 in 10,000 to 1 in 100,000 patients.1,2 For 
instance, in one population-based cohort study, the incidence 
was 14 cases in 100,000.3 It is worth noting that hepatotoxicity 
was found to be the most common cause behind drug with-
drawal or drug usage modification.2
Suspicion for DILI with a rarely reported substance may be unli-
kely in the presence of an underlying chronic liver disease such 
as hepatitis C virus (HCV) infection. Furthermore, studies that 
assess the effect of HCV on the progression of DILI in cases of 
non-acetaminophen toxicity like anabolic steroids are limited in 
number. The important risk factors for the progression of DILI are 
age (>55 years old), pregnancy and chronic alcohol consumption,4 
meanwhile diabetes mellitus is a controversial risk factor.5,6
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          Key Points:
• The clinical and biochemical presentation of drug-induced liver injury 
mimics a broad array of liver diseases.
• In some instances, liver biopsy can provide unequivocal differentia-
tion between flare-ups of chronic liver diseases and superimposed liver 
damage caused by medications.
• Short timespan between drug intake and the onset of liver injury 
manifestations, the pattern of hepatotoxicity and presence of conju-
gated hyperbilirubinemia could point to the diagnosis of drug-induced 
liver injury.
• Liver function tests should be performed before starting anabolic 
steroids, either oral or injectable, in endemic areas of asymptomatic 
chronic liver diseases.
The naturally occurring testosterone hormone can be modified 
for therapeutic use by one of two ways: esterification or alkyla-
tion of the 17α-hydroxyl group of the testosterone molecule 
(Figure 1). The alkylated forms can be taken orally and are con-
sidered a common cause of liver injury,7 whereas the esterified 
forms such as testosterone enanthate (TE) are considered de-
batable cause for DILI as these drugs are taken illicitly and case 
reports are the only available evidence.7,8 This case may open 
Figure 1. Structure of testosterone (A) and its esterified form, testosterone enanthate (B)
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the gate for larger scale studies on anabolic steroids to investiga-
te the possibility that HCV may be an important risk factor for the 
development of idiosyncratic reactions, those which are unpre-
dictable and not dose-dependent, as it is with acetaminophen.9
One important measure to define the pattern of hepatotoxicity 
is the R value which is equal to serum (ALT/ALT upper limit of 
normal) ÷ (Alk P/Alk P upper limit of normal). This classification 
was proposed by Zimmerman and later adopted by the Coun-
cil for International Organisation of Medical Sciences (CIOMS), 
where the patterns of acute liver injury are determined as fo-
llows i) Hepatocellular: R value ≥ 5 ii) Mixed hepatitic/cholesta-
tic: R value between 2-5 iii) Cholestatic pattern R value ≤ 2.4,10 
Our case is an example of the mixed pattern. A major limitation 
facing this classification is that elevations in biochemical para-
meters, such as the ALT, can represent an adaptive response to 
the drugs and may not point out a true injury.11
The Case
A 69 year-old Egyptian male patient presented to our emergency 
room with an acute onset of jaundice, abdominal swelling and 
itching. Three weeks before presenting to our emergency room, 
Shohdy KS, et al. Esterified Anabolic Androgen-Induced Liver Injury in a Hepatitis C Virus-Positive Patient: A Case Report
Duration of culprit drug therapy 7 days
Time to onset of symptoms 8 days
Clinical presentation Jaundice, abdominal pain, pruritus, 
choluria
Time to admission 21 days
Initial R ratio 3.3 (Mixed pattern)
Time to first detection of lab 
abnormalities
21 days
Liver function tests at time of 
admission
ALT= 6.9 times ULN*, AST= 5.9 times 
ULN, ALK P=2.25 times ULN. total bili-
rubin 30.0 mg/dL, direct 28.0 mg/dL.
After 5 days of admission ALT, AST and Alk P showed mild decli-
ne, total bilirubin 27.0 mg/dL, direct 
25.0 mg/dL.
Time to resolution Not applicable
Table 1. Case Summary.
Lengend: ULN= the upper limit of normal.
Criteria Possible Scores
Present Case 
Score
Rationale
Time between drug start and liver enzyme 
elevations
+1 to +2 +2
Receiving the drug for the first time is given 2 points if 
the time to onset is 5 to 90 days.
Course of the reaction -2 to +3 +1 Mild resolution of LFTs in 20 days after drug discontinuity
Risk factors 0 to +2 +1 Age> 55 yrs.
Concomitant drugs -3 to 0 0 Tadalafil not known to be hepatotoxic.21
Competing non-drug causes -3 to +2 -1 Potential HCV activity
Previous Information on hepatotoxicity of the drug 0 to +2 +2 See discussion section.
Rechallenge -2 to +3 0 Not applicable
Score >8 points definite 
6-8 points probable 
3-5 points possible 
1-2 points unlikely 
<0 points excluded
+5 Possible
Table 2. RUCAM criteria to prove causality in DILI cases.
he sought medical advice for his erectile dysfunction issue. He 
has a long history of diabetes and hypertension which were 
controlled with glimepiride 3 mg and bisoprolol 5 mg respecti-
vely. His andrologist prescribed tadalafil 5 mg and testosterone 
enanthate 250 mg, the latter, which was prescribed for unclear 
reason, was given twice intramuscularly with a one-week in-
terval. The first injection caused an epigastric pain described 
by the patient as a burning sensation with slight abdominal 
tenderness, but it was after the second injection that caused his 
condition to worsen with an acute onset of jaundice, abdominal 
swelling, itching and dark colored urine and pale stools. The-
se symptoms have continued to the time of admission to our 
emergency room. On physical examination he was afebrile, the 
pulse was 55 bpm and his blood pressure was 135/75 mmHg. 
The jaundice was strikingly apparent in his entire skin and mu-
cous membranes, and the head and neck examination revealed 
bilateral parotid enlargement. The patient denied alcohol con-
sumption or any herbal or dietary supplements.
 
Abdominal examination revealed the presence of generalized 
abdominal distention, epigastric tenderness, enlargement of 
the liver with a sharp border and shifting dullness revealed 
ascites. His past medical history is unremarkable for previous 
surgeries or chronic morbidities except for an attack of myocar-
dial infarction. His liver function tests (LFTs) showed a mixed 
hepatitis/cholestasis pattern where alanine transaminase (ALT) 
was 240 U/L [6.9 times the upper limit of normal], asparta-
te transaminase (AST) 264 U/L [5.9 times the upper limit of 
normal], alkaline phosphatase (Alk P) 270 U/L (2.25 times the 
upper limit of normal), hence the calculated R value is 3.3, total 
bilirubin 30.0 mg/dL, (direct 28.0 mg/dL), albumin 3.7 g/dL and 
eosinophils 2%. The abdominal ultrasound revealed hepatome-
galy with no dilatation of the intrahepatic biliary tract radicles 
with normal sized kidneys and his autoimmune and virology 
screening was negative except that his HCV RNA was qualitati-
vely positive. The patient was not aware of being HCV positive 
before. We restricted our screening to the recommendations of 
the American College of Gastroenterology clinical guidelines for 
investigating a case of suspected DILI that included anti-nuclear 
antibody, anti-smooth muscle antibody, IgG level, Anti-HAV IgM, 
HBsAg, anti-HBc IgM, anti-HCV and HCV RNA.10 On follow-up, 
after 5 days of admission, the total and direct bilirubin were 27 
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mg/dl & 25 mg/dl respectively and LFTs were ALT 186 U/L, AST 
203 U/L, Alk P 189 U/L.
The symptoms of the patient were improving slowly on with-
drawal of TE.  Simultaneously, intravenous fluids and N-ace-
tylcysteine were administered while monitoring for the deve-
lopment of coagulopathy or encephalopathy. There were no 
clinical benefits found in the literature regarding the use of ur-
sodeoxycholic acid (UDCA) in the mixed hepatotoxicity pattern 
except for lowering alkaline phosphatase levels.12 The patient 
left against medical advice so a follow-up could not be repor-
ted. Written informed consent was obtained from the patient 
for publication of this case report.
Discussion
The clinical and biochemical presentation of drug-induced liver 
injury mimics a broad array of liver diseases. However, the most 
common clinical presentation resembles hepatocellular jaun-
dice or cholestatic liver disease.13 According to the LiverTox® 
(Available from: http://livertox.nih.gov/AndrogenicSteroids.ht-
m#top, updated 2015 June 23; cited 2015 July 21) toxicity with 
injectable anabolic steroids (esterified testosterone) is not well 
documented. In the review of the literature, we found two cases 
that developed liver toxicity (acute cholestasis) while using es-
terified testosterone,14,15 and one case that developed a hepatic 
adenoma.16 Moreover, preclinical studies showed that long term 
use of esterified testosterone like testosterone enanthate can 
cause an increase in liver enzymes and a decrease in HDL-cho-
lesterol.17 On the other hand, one study by Marquardt et al 
in 1964 showed failure of esterified anabolic steroids (non C 
17-alkylated) to produce abnormal liver function tests.8 Further 
studies are needed to assess the short and long term effects of 
esterified testosterones on the liver.  
The differential diagnoses of this case includes acute viral he-
patitis, autoimmune hepatitis and other less common viruses 
e.g. cytomegalovirus and Epstein-Barr virus. Acute hepatitis C 
can masquerade as DILI in 1.3% of cases especially with acute 
hepatocellular injury and suggestive HCV RNA testing.10 Howe-
ver, these two findings do not apply to our case, for example, 
Chalasani et al. recruited 300 cases with suspected DILI in a 
prospective study and found that DILI is an unlikely diagnosis 
with only 9 positive cases (3%) and in 4 of them the final diag-
nosis turned out to be an HCV infection.5 Another study, recrui-
ted 570 cases, has excluded 59 cases for an alternative cause 
of injury which was viral hepatitis on 11 occasions. A total of 
446 (78%) cases were deemed to be idiosyncratic hepatotoxi-
city.6 Although viral hepatitis is a valid differential diagnosis in 
suspected DILI cases, studies have shown that it is a less likely 
cause of injury in idiosyncratic liver injury.
The existence of underlying liver disease can still hinder a strai-
ghtforward diagnosis of DILI in general, since the flare-up of 
the chronic disease caused by viral hepatitis cannot be ruled 
out completely. In some instances, liver biopsy can provide 
unequivocal differentiation between flare-ups and superimpo-
sed damage by the offending drug. Other important clues are 
the short time period between the culprit drug intake and the 
onset of clinical manifestations, the pattern of hepatotoxicity 
and presence of conjugated hyperbilirubinemia.1,13 We depen-
ded on these previous three clues for considering DILI as a 
possibility in this case. We have also implemented the Roussel 
Uclaf Causality Assessment Method (RUCAM), which was de-
veloped in 1993 by a group of international experts;4 our case 
achieved a possible (+5) score (refer to Table 2). An interesting 
review from the Spanish Group for the Study of Drug-Induced 
Liver Disease points out the strengths and weaknesses of the 
available causality assessment methods.18
The prevention of idiosyncratic drug reactions is a daunting 
task; however the future is promising with progress towards 
the development of biomarkers, where the genetic profile of 
every person can be screened to determine whether a certain 
drug can cause an idiosyncratic toxicity. This advancement will 
be very important to those with chronic liver disease, for exam-
ple, Abacavir which is an antiviral used in human immunodefi-
ciency virus (HIV) treatment, can cause severe hypersensitivity 
reactions and hepatotoxicity.  These reactions have been found 
to occur in patients with human leukocyte antigen-B*5701 and 
genetic screening prior to Abacavir intake is strongly advised 
by the Food and Drug and Administration (FDA) to prevent such 
severe reactions.19 In addition, the HLA-B*5701 genotype has 
been linked with flucloxacillin induced liver injury.20 Though 
these genetic linkage studies can predict what was thought 
to be unpredictable idiosyncrasies, there is still a long way to 
reach widely accepted predictive biomarkers.
Conclusion
Two clinical notes learnt from this case; first, LFTs are recom-
mended before starting anabolic steroids either oral or injecta-
ble in endemic areas with asymptomatic chronic liver diseases 
such as HCV. Second, in any case of acute liver injury within 
endemic areas, stigmata of chronic liver disease have to be 
investigated thoroughly by clinical, biochemical and radiological 
means. Physicians have to take into consideration that HCV as 
well as other chronic diseases e.g. alcoholic liver disease and 
nonalcoholic fatty liver disease (NAFLD) leave the liver suscepti-
ble to steroid toxicity. In contrast to alcoholic hepatitis and HBV, 
HCV patients do not experience icteric flares, which along with 
the history of hepatotoxic agent intake, latency to DILI onset, 
and biochemical and histological features at presentation raise 
the index of suspicion to DILI. However, due to diagnostic limita-
tions it is difficult to distinguish with a high-degree of certainty 
between a spontaneous disease flare-up and a DILI episode.
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